Sirima Sangkapat

Dr. Sirima Sangkapat


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BCBenchawan Chamsai
Benchawan Chamsai
SSSirima Sangkapat
Sirima Sangkapat
POPraneet Opanasopit
Praneet Opanasopit
Wipada SamprasitWipada Samprasit
Wipada Samprasit
Topical film-forming sprays of chlorhexidine gluconate (CHG-FFS) were developed for antiseptic application. Various polymers and solvents were studied for their potential as film-forming polymers and solvent systems, respectively. To produce CHG-FFS, the optimal polymer and solvent were selected, and their physicochemical properties were evaluated. The in vivo evaluation of CHG-FFS was investigated for the satisfaction of the dosage forms, time required for the film formation, film appearance, and adhesion on the skin. Antibacterial activity was also studied in vitro and in vivo. The optimized formulation was assessed for the in vitro cell line evaluations of the cytotoxicity and wound healing. The results demonstrate that Eudragit® S100, Eudragit® L100, and polyvinyl alcohol (PVA) have the ability to be used as film-forming polymers in an ethanolic solution. A clear and flexible film was obtained from transparent homogenous solutions of CHG-FFS after actuation. They generated the fast thin film formation on the skin with the satisfaction of the dosage forms. Furthermore, the formulations inhibited the growth of Staphylococcus aureus in vitro and provided antiseptic activity in vivo. However, PVA was found to be an optimal film-forming polymer for promoting CHG adhesion on the skin. The CHG-FFS obtained from the PVA also provided a CHG film, which was non-toxic to human skin cells and did not interfere with the wound healing process. Therefore, the developed CHG-FFS could be a promising candidate for topical antiseptic application.

1 November 2020 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
SSSirima Sangkapat
Sirima Sangkapat
PMParanee Meetam
Paranee Meetam
LSLawan Siangjong
Lawan Siangjong
RCRatchanaporn Chokchaisiri
Ratchanaporn Chokchaisiri
ASApichart Suksamrarn
Apichart Suksamrarn
SSSunhapas Soodvilai
Sunhapas Soodvilai
Cisplatin is a widely used chemotherapy for solid tumors; however, its benefits are limited by serious nephrotoxicity, particularly in proximal tubular cells. The present study investigated the renoprotective effect and mechanisms of germacrone, a bioactive terpenoid compound found in Curcuma species on cisplatin-induced toxicity of renal cells. Germacrone (50 and 100 µM) attenuated apoptosis of human renal proximal tubular cells, RPTEC/TERT1 following treatment with 50 µM cisplatin and for 48 h. Co-treating RPTEC/TERT1 cells with cisplatin and germacrone significantly reduced cellular platinum content compared with cisplatin treatment alone. The effect of germacrone on organic cation transporter 2 (OCT2) which is a transporter responsible for cisplatin uptake was determined. Germacrone showed an inhibitory effect on OCT2-mediated methyl-4-phenylpyridinium acetate (3H-MPP+) uptake with IC50 of 15 µM with less effect on OCT1. The germacrone’s protective effect on cisplatin-induced cytotoxicity was not observed in cancer cells; cisplatin’s anti-cancer activity was preserved. In conclusion, germacrone prevents cisplatin-induced toxicity in renal proximal tubular cells via inhibition OCT2 transport function and reducing cisplatin accumulation. Thus germacrone may be a good candidate agent used for reducing cisplatin-induced nephrotoxicity.

27 February 2023 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
RBRattiporn Boonnop
Rattiporn Boonnop
PMParanee Meetam
Paranee Meetam
LSLawan Siangjong
Lawan Siangjong
PTPatoomratana Tuchinda
Patoomratana Tuchinda
PTPiyanut Thongphasuk
Piyanut Thongphasuk
SSSirima Sangkapat
Sirima Sangkapat

2 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
PBPenjai Thongnuanjan Bray
Penjai Thongnuanjan Bray
SSSirima Sangkapat
Sirima Sangkapat
SFSomsak Fongsupa
Somsak Fongsupa
NTNatechanok Thipboonchoo
Natechanok Thipboonchoo
NCNapason Chabang
Napason Chabang
SSSunhapas Soodvilai
Sunhapas Soodvilai
Background: Panduratin A is a bioactive cyclohexanyl chalcone exhibiting several pharmacological activities, such as anti-inflammatory, anti-oxidative, and anti-cancer activities. Recently, the nephroprotective effect of panduratin A in cisplatin (CDDP) treatment was revealed. The present study examined the potential of certain compounds derived from panduratin A to protect against CDDP-induced nephrotoxicity. Methods: Three derivatives of panduratin A (DD-217, DD-218, and DD-219) were semi-synthesized from panduratin A. We investigated the effects and corresponding mechanisms of the derivatives of panduratin A for preventing nephrotoxicity of CDDP in both immortalized human renal proximal tubular cells (RPTEC/TERT1 cells) and mice. Results: Treating the cell with 10 µM panduratin A significantly reduced the viability of RPTEC/TERT1 cells compared to control (panduratin A: 72% ± 4.85%). Interestingly, DD-217, DD-218, and DD-219 at the same concentration did not significantly affect cell viability (92% ± 8.44%, 90% ± 7.50%, and 87 ± 5.2%, respectively). Among those derivatives, DD-218 exhibited the most protective effect against CDDP-induced renal proximal tubular cell apoptosis (control: 57% ± 1.23%; DD-218: 19% ± 10.14%; DD-219: 33% ± 14.06%). The cytoprotective effect of DD-218 was mediated via decreases in CDDP-induced mitochondria dysfunction, intracellular reactive oxygen species (ROS) generation, activation of ERK1/2, and cleaved-caspase 3 and 7. In addition, DD-218 attenuated CDDP-induced nephrotoxicity by a decrease in renal injury and improved in renal dysfunction in C57BL/6 mice. Importantly, DD-218 did not attenuate the anti-cancer efficacy of CDDP in non-small-cell lung cancer cells or colon cancer cells. Conclusions: This finding suggests that DD-218, a derivative of panduratin A, holds promise as an adjuvant therapy in patients receiving CDDP.

1 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SSSirima Sangkapat
Sirima Sangkapat
RBRattiporn Boonnop
Rattiporn Boonnop
JPJeerawat Pimta
Jeerawat Pimta
NCNapason Chabang
Napason Chabang
BNBodee Nutho
Bodee Nutho
SSSunhapas Soodvilai
Sunhapas Soodvilai
Background/Objectives: Pinocembrin is a promising drug candidate for treating ischemic stroke. The interaction of pinocembrin with drug transporters and drug-metabolizing enzymes is not fully revealed. The present study aims to evaluate the interaction potential of pinocembrin with cytochrome P450 (CYP450: CYP2B6, CYP2C9, and CYP2C19) and drug transporters including organic anion transporters (OAT1 and OAT3), organic cation transporters (OCT1 and OCT2), multidrug and toxin extrusion (MATE1 and MATE2, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). Methods: The interactions of pinocembrin on drug transporters were determined in the Madin–Darby canine kidney (MDCK) cells overexpressing human (h)OAT1 or hOAT3 and in the Chinese hamster ovary (CHO-K1) cells overexpressing hOCT1, hOCT2, hMATE1, or hMATE2. The interactions of pinocembrin with BCRP and P-glycoprotein were determined in Caco-2 cells. The CYP450 enzyme inhibitory activity was assessed by a cell-free CYP450 screening assay. Results: Pinocembrin effectively inhibited the function of OAT1 and OAT3 with a half-inhibitory concentration (IC50) and inhibitory constant (Ki) of ∼2 μM. In addition, it attenuated the toxicity of tenofovir, a substrate of hOAT1, in cells overexpressing hOAT1. Based on the kinetic study and molecular docking, pinocembrin inhibited OAT1 and OAT3 via a competitive inhibition. In contrast to hOAT1 and hOAT3, pinocembrin did not significantly inhibit the function of OCT1, OCT2, MATE1, MATE2, BCRP, and P-glycoprotein. In addition, pinocembrin potently inhibited the activity of CYP2C19, whereas it exhibited low inhibitory potency on CYP2B6 and CYP2C9. Conclusions: The present study reveals the potential drug interaction of pinocembrin on OAT1, OAT3, and CYP2C19. Co-administration with pinocembrin might affect OAT1-, OAT3-, and CYP2C19-mediated drug pharmacokinetic profiles.

23 October 2026 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
SSSunhapas Soodvilai
Sunhapas Soodvilai
BNBodee Nutho
Bodee Nutho
NSNatthapat Sawektreeratana
Natthapat Sawektreeratana
TTTienthong Thongpanchang
Tienthong Thongpanchang
SSSirima Sangkapat
Sirima Sangkapat
Background: Silymarin is widely used as a hepatoprotective and nephroprotective agent. However, its potential to interact with renal organic anion transporters (OATs) remains poorly understood. This study investigated the effects of silymarin and its major constituent, silybin, on the transport functions of human (h) OAT1 and hOAT3 and transporter-mediated drug accumulation. Methods: Interactions and mechanisms of silymarin with hOAT1 and hOAT3 were studied using MDCK cells stably expressing hOAT1 or hOAT3. Results: Silymarin significantly inhibited hOAT1- and hOAT3-mediated transport in a concentration-dependent manner, with IC50 values of 0.32 and 0.65 µg/mL, respectively. Silybin also inhibited both transporters but exhibited lower potency, with IC50 values of 3.02 µg/mL for hOAT1 and 8.5 µg/mL for hOAT3. Kinetic studies demonstrated increased Kt values without changes in Jmax, indicating competitive inhibition. Molecular docking revealed strong binding affinities of multiple silymarin constituents toward the substrate-binding pockets of both transporters, supporting a competitive interaction mechanism. Functionally, silymarin significantly reduced accumulation of tenofovir, an OAT substrate drug. Consistently, silymarin attenuated tenofovir-induced cytotoxicity in hOAT1- and hOAT3-expressing cells, with a greater protective effect observed in hOAT1 cells. Conclusions: These findings indicate that silymarin inhibits hOAT1 and hOAT3 and highlight the potential for both transporter-mediated silymarin–drug interactions.